Ovrestin - cheap analogs. Ovrestin Analog - what drugs are similar in composition and action? Ovrestin Cream Analogs Russian

Prohibited with breastfeeding

Banned for receiving children

Has limitations for older people

Has limitations when problems with liver

Has restrictions on kidney problems

Ovrestin is an original drug containing an estrilla. Manufacturers - France and Holland. Like any branded preparation, Ovrestin has cheaper structural analogues and substitutes for similar action.

In the female body and at least a men's inner secretion gland produce specific hormones of steroid nature - estrogens. They affect practically all the exchange processes necessary to maintain homeostasis. There are three subspecies of estrogen: estrilla, estradiol and estro, each of which is responsible for certain biochemical processes. The main component of the drug Ovrestin is an estrilla.

The greatest concentration in the body of a woman estrius reaches during pregnancy, during the rest of the time this hormone remains at a relatively low level. Of all three subspecies, estriol is considered the least active and rapidly discontinued hormone.

However, it was revealed that the estrilla has a high specificity for receptors in the urinary system, in connection with which it began to be introduced into the therapy of such conditions, as atrophy of the mucous membrane of the lower unit of the genitourinary system, in pre-or postmenopausal periods, especially patients who have moved Operational interventions on the genitals.

Estivity, isolated on epithelial cells with specific receptors to it, improves the trophic, helps to restore the biocenosis and the acid-base equilibrium of the vagina, improves the resistance to pathogenic microorganisms, reduces the manifestation of symptoms during menopause.

Ovrestin is available in several pharmacological forms: pills for oral administration, candlelight and in the form of a cream for intravaginal administration:

The analogues of the composition of the composition are presented in various form of release: tablets, candles and cream. Full counterparts containing the component of the same name are represented by the following trade names:

1. Estor.
2. Estrocead.
3. Estriol-M Pessary.
4. Ovipol Klio.
5. Ornion.
6. Elvagin.
7. Estrojigin.

Cheap analogues of healers in tablets

Among the inexpensive drugs that have similar evidence of testimony and a similar mechanism of action, but based on another active component, the drugs of Proginov, microfallines, clumen, etc. are distinguished.

Progian

Refers to the preparations of estrogen rows, 1 tablet contains estradiol Valerat 2 mg. Estradiol is one of the subtypes of estrogen affecting the metabolism of many substances. Proginov contains synthetic estradiol, which is almost identical to the biogenic. Estradiol is the most active subtype of estrogen necessary for the normal development, functioning and trophic of the female reproductive system and many other tissues and organs. In the men's body is produced in a small number of adrenal cortex.

Progin is accepted daily by 1 tablet during the first 3 weeks. Next it is recommended to make a single break. Feature, duration and need for further therapy is solved together with the attending physician. Indications include hormonal replacement therapy in cases of identified estrogen failure in women in postmenopausal period.

Contraindications:

1. Pathological sensitivity to the constituent drug.
2. Suspicion or diagnosed breast chaser at any stage.
3. Estrogen-dependent malignant tumor of any localization.
4. Bleeding from sex tract without a reasonable cause.
5. Excessive expansion of endometrial resistant to treatment.
6. Violation of the work of the hemochaguing system, a tendency to thrombosis.
7. Dysfunctional pathology, liver tumors.
8. High level triglycerides to blood.

Ovestin and Proginov in its composition contain estrogens, but the various fractions of their fractions: Ovrestina - estriol, in proghes - estradiol, resulting in drugs have some differences in the testimony to use.

The role of estrogen

Side effects:

1. Cefalgia, dyspepsia.
2. Skin hyperimmune manifestations in the form of rashes.
3. Uterine bleeding, changes in the amount of selected menstrual blood, intermented bleeding.
4. Changes in body weight, overflow.
5. Pain in lactic glands.
6. Detection of mood, dizziness, violation, tachycardia.

Microfollins

Synthetic estrogen, 1 tablet contains 0.05 mg of ethinyl estradiol. Microfollins contains ethinyl estradiol, which is similar to the human estrogen. Causes the proliferation of the inner layer of the uterus, improves the trophy of the fabrics of the female reproductive system. Clears a powerful antandogen effect, as a result of which is widely used in prostate cancer therapy.

It is accepted inside, the dose is painted personally for each patient. When the prostate carcinoma is assigned a starting dose of 0.05-0.1 mg three times a day, which is further declining for supporting therapy. With a long lack of menstruation not related to pregnancy, women are 0.05 mg daily for 20 days, after which therapy continues progesterone for 5 days. To stop the lactation for 3 days, it is necessary to take 1 tablet daily, on - by ½ tablet. With acne disease - half or 1 tablet daily.

Microfollins

Indications:

1. Disorders of the menstrual cycle (no menstruation, small amount of blood secured, uterine bleeding, intermented bleeding).
2. Termination of lactation.
3. Acne.
4. Prostate carcinoma.
5. Climax.

Contraindications include estrogen-dependent tumor diseases of various localization, malignant neoplasms of the breast, tendency to thrombosis and / or thromboembolic complications in history, violation of the functioning of hepatocytes.

Unlike solidin, microfallines contains a more active estrogen fraction - ethinyl estradiol, and therefore has a wider spectrum of indications and various application schemes.

Side effects: Pathological reactions to components, cephalgic syndrome, nausea, vomiting, osteoporosis associated with an imbalance in calcium exchange, the pathology of the bone marrow, its hypoplasia, swelling.

Klimen.

This is an estrogen progesterone drug. 1 Clevenna tablet contains 2 mg of estradiol and 1 mg of ciproterone acetate. The klimen contains synthetic estradiol, which is identical to the endogenous estradio. It compensates for estradiac insufficiency arising in patients in the menopacteric period, thereby decreasing symptoms associated with the onset of menopause.

Ciproterone acetate is a synthetic analogue of endogenous progesterone, which has an active antidegengenic and antiproliferative effect. Due to the fact that the isolated use of estradiol causes an endometrial hyperproliferation, the addition of a component of the Gestagenic row allows you to exclude this undesirable effect.

The clumen applies according to the following schemes:

1. If similar drugs were not previously used, then the clumen begin to take from the 5th day of the menstrual cycle on one tablet daily.
2. If you need to transition from another hormonal drug, the reception of the climax starts immediately after the end of the previous course, without interruption.

Packaging contains 21 tablets for two colors (white and pink), which are used daily. During the first 11 days, they take 1 white tablet, the next 10 days is 1 pink tablet. Indications: Estrogen deficiency in pre- and postmenopausal, prevention of osteoporosis in these periods (in women with increased risk of disease).

Contraindications:

1. Hypersensitivity to components.
2. Suspicion or established breast cancer, estrogen-dependent tumor of another localization.
3. Metrragia without a diagnosed cause.
4. Endometry growth.
5. Blood hypercoagulation (synchronome thromboembolism).
6. Pregnancy and breastfeeding period.
7. Hepatocyte dysfunction.
8. Increased content of triglycerides in the blood.

The clumen differs from solidin more active estradiol and an additional component - ciproterone, thanks to which the clumen can be applied and shown to patients with increased risk of osteoporosis. Dosage and method of use will also differ.

Cheap analogues in candlelight and gel

Suppositories intended for intravaginal administration and gels containing female sex hormones have their advantages, among which: a more local impact, in this connection it is possible to use small dosages, which helps to reduce undesirable effects, reduces the number of contraindications.

Ovipol Klio.

Dosage group - preparations containing female sex hormones estrogen rows. The active component is an estrium, which is contained in 1 candle in a dosage of 500 μg. There is a set of receptors that focus mainly in the body of the uterus, vagina, chest, hypothalamus, hypophysies, and so on.

Combining receptors located on the surface of the cells of the female sexual system, the drug improves blood circulation, metabolism, enhances the proliferation of the inner layer of the uterus, equilibrate the acid-alkaline state, normalizes normal biocenosis in the vagina cavity. Also steroid hormone affects carbohydrate and fat exchange.

Apply the drug intravaginal, 1 candle for the night (before bed). The duration of reception is 2-3 weeks. It is not recommended to take more than 1 candles per day.

Indications for use:

1. Estrogenous failure during the period of Klimaks or Prelimax, manifested by the thinning of the mucous membrane of the urogenital tract and other symptoms, pre- and postoperative period (operations with intravaginal access).
2. Menopause, accompanied by characteristic symptoms, bringing discomfort and / or violation of general well-being.
3. Infertility (if the reason is due to a cervical factor).
4. Pain during sexual intercourse, dryness, itching vagina, enuresis.
5. For diagnostic purposes.

Contraindications include hyperreaction on the components of the drug, the pathology of the blood coagulation system by type of hypercoagulation, various manifestations of thrombosis in history, severe liver pathology, estrogenetic tumors of the reproductive system, metrragia without a reasonable cause, pregnancy.

Hypercoagulation

The original and its analogue OVIPOL Klio differs only in the price category, the latter is cheaper.

Side effects:

1. Discomfort, irritation at the place of introduction.
2. Voltage and pain in breast glands.

Estate

Natural estradiol in the form of a gel for no use. 1 g of gel contains 0.6 mg of the active substance, with one press, 1.25 g of gel is released, which corresponds to 0.75 mg of estradiol. The use of estradiol transdermally allows the drug to act, bypassing the liver, which minimizes a negative effect on hepatocytes and increases the half-life.

The estodel replenishes the deficiency of estrogen during the period of Klimaks and Pleymax. 1 Gel dose, which is equal to 1 pressing (0.75 mg of the active component), are applied to extensive areas of intact skin (belly, forearm, loin or other) thin layer 1 time per day after the morning or evening toilet of the skin. The duration of use is 21-28 days a month. The dose may vary (on average no more than 2.5 g of gel per day) In the future, it is necessary to make a single break. Further therapy defines the doctor individually for each patient.

Indications:

Contraindications are similar to the drug OVIPOL Klio.

The estimary differs from solidin the pharmacological form and the method of application (a collection of gel, intended for transdermal administration, solidin - cream, for vaginal administration). Preparations contain different estrogen fractions, dosages.

Unwanted effects:

EstroCad.

The medical preparation is available in suppositories containing 0.5 mg of estriol. The mechanism of action is similar to evidence. The estroca is used according to the following schemes:

1. In atrophic manifestations of the lower unit of the urogenital tract on 1 suppository daily for 3 weeks, then the dose is reduced and is 0.5 mg (1 candle) twice a week.
2. Before and after surgical interventions with vaginal access in women in the post-block cell period - for 2 days, take 0.5 mg daily (in a preoperative period) and 1 candle twice per week (in the postoperative period).
3. With a diagnostic purpose, it is used within a week a day before taking a smear.

Indications include replacement therapy with estrogen in the case of their insufficiency (with dryness and thinning of the mucous membrane of the urogenital tract, pain with sexual intercourse, itching and discomfort in the vagina, enuresis of an easy degree), in the treatment of patients in the period of menopause or postmenopause, which will have to operate with vaginal access or after it. In order to further diagnose in suspected atrophy, after taking a smear from the cervical canal.

Contraindications coincide with the contraindications of the drug OVIPOL Klio. Estrocead and Ovrestin are similar to all criteria, the only difference is a different manufacturer and price of drugs.

Unwanted effects: stress, heat and soreness of the chest, peripheral edema, the presence of transparent mucosal discharge, an increase in blood pressure, muscle fibers, cephalgic syndrome, skin hyperpigmentation.

Replays of the drug in ampoules

Ovrestin is not available in the form of ampoules, but some pharmacological firms produce drugs, as part of which there are hormonal means for parenteral applications.

Synestrol.

The medical preparation refers to hormone agents used in the pathology of the sexual sphere. Active substance - hexesterrol. One ml contains 1 mg or 20 mg of Hexoestrolum.

Hexesterol is an estrogenic synthetic drug of a non-steroidal structure. Specifically impacting receptors, improves metabolic processes, blood circulation, prevents the calcium flushing from the blood and prevents bone fragility in women in the post-block cell period.

The drug is introduced deep into the engineer muscle of 1-2 mg daily, the duration of the course depends on the reading:

Indications: ovarian hypofunction, which is manifested by underdevelopment of female genital organs, amenorrhea, disorders in the period of menopause and postmenopause, breast cancer therapy in women after 60 years, prostate cancer therapy.

Contraindications: dysfunctional states of liver and kidneys, mastopathy, the presence of foci of endometrium tissue, metrorragia, tumors in women up to 60 years, diabetes mellitus, blood hypercoagulation and complications associated with it, pathological sensitivity to the drug components.

Overestin and synestrol are distinguished by the active substance, the form of the issue, the method of administration, the course of therapy, indications and contraindications.

Side effects:

Follikulin

Refers to estrogen intended for parenteral administration in cases of pathology in the sexual system. 1 ml of solution contains 1 mg of estron. The mechanism of action is similar to evidence.

Method of application: The drug is injected intramuscularly, the dosage is selected individually. Usually the drug is prescribed 1-2 ml daily from 15-17 days to 1-2 months and more. The next stage is assigned progesterone intramuscularly within 5-8 days.

With the weakness of generic activity or torsion of pregnancy, 4-5 ml is prescribed in 2-3 hours before the introduction of rhodesmooling drugs.

Indications:

Contraindications are identical to the list of restrictions when taking Orestin and other analogues. Folliculin is characterized by an active component, method of application and form of release. Unwanted effects are similar to evidence.

There are contraindications. Consult your doctor.

Preparations containing estriol (ESTRIOL, ATX code (ATC) G03CA04):

Commercial names abroad (abroad) - Aacifemine, Evalon, Hormomed, Klimadoral, Klimax-E, Oekolp, Orgestriol, Orgastyptin, Ortho-Gynest, Pausanol, Physiogine, Styptanon, Synapause, Triovex, Trophicreme, Xapro.

Ovrestin in Candle - Official Instructions for Application:

Clinical and Pharmacological Group:

Estrogenic drug.

pharmachologic effect

Estrogenic drug. Analogue of a natural female hormone. Estimates the deficit of estrogen in women in the postmenopausal period and weakens the symptoms of postmenopause. Most effective in the treatment of urinary disorders. In atrophy of the mucous membrane of the lower sections of the urinary tract, the estrilla contributes to the normalization of the epithelium of the urinary tract and helps to restore normal microflora and physiological pH into the vagina. Increases the resistance of the epithelial cells of the urinary tract to infections and inflammation, reducing such complaints as soreness during sexual intercourse, dryness, itching in the vagina, reduces the likelihood of vaginal infections and urinary tract infections, contributes to urination normalization, prevents urinary incontinence.

Unlike other estrogen, the estriol has a short period of action, since it is held in the cells of the cells of the endometrial during a short period of time. It is assumed that the disposable administration of the daily dose does not cause endometrial proliferation. Therefore, the cyclic administration of the progestogen is not required and no bleeding occurs. In addition, it is shown that estrix does not increase the mammographic density.

Pharmacokinetics

Suction

When applying the drug inside, as well as local estriol is quickly and almost completely absorbed.

Cmax estriot in plasma is achieved after 1-2 hours after intravaginal use.

Distribution

The plasma almost all (90%) estrilla is associated with albumin and, unlike other estrogen, is practically not associated with globulin connecting sex hormones (GSPG).

Election

The removal of estriol (in the bound form) is carried out mainly by the kidneys; About 2% is excreted through the intestines unchanged. The removal of metabolites with urine begins after a few hours after applying the drug and lasts 18 hours.

Indications for the use of the Preparation of Ovrestin®

• replacement hormone therapy (UGT) for the treatment of atrophy of the mucous membrane of the lower departments of the urinary tract associated with estrogenic failure;
• pre- and postoperative treatment of women in the postmenopausal period during operations with vaginal access;
• with a diagnostic goal with an unclear results of cytological research of the cervix (suspicion of the tumor process) against the background of atrophic changes.

Method of application and dosage

The accository should be entered into the vagina overnight before bedtime.

In the treatment of atrophy of the mucous membrane of the lower departments of the urinary tract, 1 suppository is prescribed per day during the first weeks, followed by a gradual decline in the dose based on the relief of symptoms, until a supporting dose (i.e. 1 suppository 2 times a week).

With pre- and postoperative therapy of women in the postmenopausal period, during surgical interventions of vaginal access 1 suppository per day for 2 weeks before the operation is prescribed; 1 Suppository 2 times a week for 2 weeks after surgery.

With the diagnostic purpose, 1 suppositorys are prescribed in the diagnostic purpose of the cervical research of the cervix in the day during the week before taking the next smear.

At the beginning or in the continuation of the treatment of postmenopausal symptoms, it is necessary to apply the smallest efficient dose for the shortest period of time.

In women who do not receive UGT, or women who are translated from continuous reception of a oral combined drug for HGT, treatment with Ovevestin® can be started on any day. Women who are moving from the cyclic mode of reception of drugs for the UGT should begin treatment with Ovevestin® 1 week after the cancellation of the TSR drugs.

Side effect

As in the case of the use of any other drug, which is applied on the surface of the mucous membranes, Ovrestin® suppositories can sometimes cause local irritation or itching.

Sometimes sensitivity, tension, pain, increase in the size of the mammary glands can occur. These undesirable reactions are usually short and passing, but at the same time may indicate the use of too high dose.

Also noted acyclic bleeding, breakthrough bleeding, metroralia.

In the UGT using estrogen-pro-contained-containing drugs, the following side effects were also observed, whose relationship was not proven using OVESTIN:

• benign and malignant estrogen-dependent neoplasia (endometrial cancer and mammary glands);
• venous thromboembolism (thrombosis of deep veins of the feet or pelvis, embolism of the vessels of the lungs) more often occurs when the UGT is used than in the absence of therapy;
• myocardial infarction, stroke;
• cholelithiasis;
• skin and subcutaneous diseases (chlorism, multiform erythema, noded erythema, hemorrhagic purpura);
• dementia;
• raising libido.

Contraindications for the use of the drug Ovevestin®

• mounted, a history of or suspect of breast cancer;
• diagnosed estrogen-dependent tumors or suspicion of them (for example, endometrial cancer);
• bleeding from vagina unclear etiology;
• uncured endometrial hyperplasia;
• the presence of venous thrombosis is currently in history;
• active or recently transferred thromboembolic disease of the arteries (for example, angina, myocardial infarction);
• the liver disease in the acute stage or disease of the liver is in history, after which the indicators of the liver function returned to the norm;
• porphyry;
• installed increased sensitivity to active substance or to any of the aid of the drug.

Carefully

If any of the following states is present or this state was noted earlier and / or worsened during preceding pregnancies or previously hormonal treatment, then such a patient should be under the direct supervision of the doctor. It must be borne in mind that these states can recur or deteriorate during treatment with Ovevestin®, especially if present:

• leiomioma (fibromes of uterus) or endometriosis;
• transferred thromboembolic violations or existing risk factors such violations;
• risk factors for estrogen-dependent tumors, for example, 1st degree of heredity for breast cancer;
• arterial hypertension;
• benign liver tumors (for example, liver adenoma);
• diabetes mellitus with the presence or absence of a vascular component;
• cholelithiasis;
• jaundice (including a history of preceding pregnancy);
• liver failure;
• migraine or severe headache;
• system red lupus;
• endometrial hyperplasia in history;
• epilepsy;
• asthma;
• otosclerosis;
• family hyperlipoproteinemia;
• pancreatitis.

Application of the Preparation of Ovestin® during pregnancy and breastfeeding

Ovrestin® is contraindicated during pregnancy. In the event of pregnancy during therapy, Ovevestin® preparation, treatment must be canceled immediately.

The results of most epidemiological studies conducted by the present relatively unintentional effects of estrogen on the fruit indicate the absence of teratogenic or fetotoxic effects.

Application with violations of liver function

The drug is contraindicated in the disease of the liver in the acute stage or disease of the liver in history, after which the functions of the liver function returned to the norm.

With liver failure, use the drug with caution.

Application with violations of the kidney function

Estrogens can cause fluid delay, and therefore patients with impaired kidney function should be under careful control of the doctor. In the terminal stage of chronic renal failure, there must be special control in connection with the possible increase in the level of circulating active components of the Ovrestin.

special instructions

For the treatment of postmenopausal symptoms, the UGT must begin only with respect to symptoms that adversely affect the quality of life. In all cases, it is necessary to carry out a thorough assessment of the risk and benefits of treatment at least once a year. The UGT should continue only for a period of time when the benefits exceed the risk.

Medical examination / observation

Before starting or renewing the UGT, it is necessary to establish a detailed individual and family history. Based on the anamnesis, contraindications and prevention on the use of the drug, it is necessary to conduct a clinical examination, including the survey of the organs of the small pelvis and the mammary glands. During treatment, it is recommended to conduct periodic medical examinations, the frequency and character of which are individual, but at least 1 time per year. Women should be informed about the need to communicate a doctor about changes in mammary glands. Research, including mammography, must be carried out in accordance with generally accepted survey standards.

Therapy should be discontinued in the event of a contraindication and / or when the following states occur:

• jaundice and / or deterioration of the liver function;
• significant increase in blood pressure;
• resumption of headache by type of migraine;
• pregnancy.

Hyperplasia Endometrial

To prevent stimulation of endometrial, the daily dose should not exceed 1 suppository (500 μg of estriol). It should not be used this maximum dose for more than 4 weeks.

Cancer of the mammary glands

Based on the results of a randomized, placebo-controlled study on the Female Health Initiative Program (WHI) and epidemiological studies, including a study of a million women (MWS), an increased risk of breast cancer in women who took estrogens, estrogen-protestagen-containing combinations or Tibolone For the UGT for several years. For the whole of HGT, the increased risk becomes noticeable after several years of use and increases with the duration of the reception, but returns to the initial level through several (maximum 5) years after the cessation of treatment.

In the study of MWS, the relative risk of breast cancer occurs when using conjugated horsepower estrogen (more) or estradiol (E2) was higher when progestogen was added, both in cyclic and continuous reception, regardless of the type of progestogen. Not received confirmation of the change in the degree of risk in various ways of administration.

In the WHI study, the use of the combined preparation of the conjugated horse estrogen and the medroxyprogesterone of acetate (easily + mR) was associated with a continuous reception with the occurrence of cancer tumors of the mammary glands, which were slightly larger in size and more often had metastases in local lymph nodes compared to placebo.

With regard to OVESHIN, such a risk is not known. In a recent population study, the case-control with the participation of 3345 women with invasive breast cancer and 3454 women in the control group it was shown that the use of estriol, unlike other estrogen, was not associated with an increase in the risk of developing breast cancer. In this regard, it is important that the patient is aware of the risk of developing breast cancer in a ratio with a known benefit of the UGT.

Venous thromboembolia

The UGT is connected with a higher relative risk of the development of venous thromboembolism (VTE), i.e. Thrombosis of deep veins or lung embolism. In one randomized controlled study and in epidemiological studies, it was found that the degree of risk for women receiving the GHT is 2-3 times higher than for patients who did not receive such treatment. It has been established that for women who do not use UGT, the number of cases of VTE, which may occur for a 5-year period, is about 3 cases for each 1000 women aged 50-59 years and 8 cases for each 1000 women aged 60-69 years. In healthy women using UGT for 5 years, the number of additional cases of VTE during the 5-year period should be 2-6 cases (on average 4) for each 1000 women aged 50-59 years and 5-15 cases (on average 9) for each 1000 women aged 60-69 years. VTE is most likely during the first year of the UGT than in a later date. In relation to OVESHIN, such a risk is unknown.

Typically, the corresponding individual or family history, the obesity of the high degree (CMT\u003e 30 kg / m2) and the systemic red lupus) are appropriate individual or family history. There is no single opinion regarding the role of varicose veins in the development of VTE.

Patients with Aite in history or with mounted thromboembolic states have an increased risk of VTE. UGT can increase this risk. In order to eliminate the predisposition to the formation of thromboms, a thorough collection of individual and family history in relation to thromboembolism or a repeated spontaneous miscarriage is needed. As long as a thorough assessment of thromboembolic factors is carried out, anticoagulant treatment should not be treated or carried out. With regard to women who are already treated with anticoagulants, careful consideration of the benefit value / risk of HRT is required.

The risk of VTE may increase with prolonged immobilization of the patient, extensive injury, the large amount of surgical intervention. After the surgical operation, it is necessary to pay special attention to preventive measures to prevent VTE. In cases where long-term immobilization is inevitable after the optional operation, in particular, after an abdominal surgical operation or orthopedic operation on the lower limbs, if possible, it is necessary to provide for a temporary termination of the UGT for 4-6 weeks before the operation. If Ovestin® is applied according to the indication "Pre- and postoperative treatment of women in the postmenopausal period with vaginal access operations" it is necessary to provide preventive treatment for preventing thrombosis.

If after the start of treatment with the preparation of Ovestin® develops VTE, then the treatment of the drug must be discontinued. Patients should be informed about the need to immediately appeal to the doctor if they feel the symptom of potential thromboembolism (for example, painful swelling of legs, sudden chest pain, shortness of breath).

In randomized controlled studies, it has not received confirmation of the positive effect of continuous reception of a combination of conjugated estrogen and acetate (MPA) acetate (MPA) for the state of the cardiovascular system. In two large clinical studies of WHI and HERS (the study of the heart and estrogen-progestin of substitution therapy) confirmed the likelihood of a possible increase in the risk of cardiovascular diseases during the first year of application and the absence of general benefits.

There are only limited data for the UGT drugs, so there is no confidence that these results also apply to other drugs for the WGT.

In a large randomized study (WHI), it was found that an increased risk of ischemic stroke can be considered as a side effect in healthy women during treatment with a continuous admission of a combination of conjugated estrogen and mra. For women who do not apply the GHT, the number of cases of stroke, which may occur within a 5-year period, is about 3 cases for each 1,000 women aged 50-59 years and 11 cases for each 1000 women aged 60-69 years. It has been established that for women who use conjugated estrogens and mRs for 5 years, the number of additional cases increases by 0-3 cases (on average 1) for each 1000 patients aged 50-59 years and 1-9 cases (on average 4 ) Each 1000 patients aged 60-69 years old. It is not known whether the increased risk and other drugs for the UGT are distributed.

Ovarian cancer

Long (at least 5-10 years) monotherapy with estrogens (as the UGT) women who have moved operations in the uterus are associated with an increased risk of ovarian cancer, which was established in several epidemiological studies. It has not been proven that long-term combined HRT or monotherapy with low-active estrogens (for example, Ovrestin®) has a different risk.

Other states

Estrogens can cause fluid delay, and therefore patients with impaired kidney function and cardiovascular failure must be under careful control of the doctor. In the terminal stage of chronic renal failure, there must be special control in connection with the possible increase in the level of circulating active components of the Ovrestin.

Estriol is a weak inhibitor of gonadotropin and does not have other significant effects on the endocrine system.

Not received convincing confirmation of improved cognitive function. In WHI, the test received a certificate of increased risk of possible dementia in women, which began to apply a continuously combination of conjugated estrogen and MRA in continuous mode after 65 years. It is not known whether these results are applicable to younger women who are in postmenopausal use other drugs for the UGT.

Overdose

Acute toxicity of estriol in animals is very low. Overdose of the Preparation of Ovestin® with vaginal administration is unlikely. However, in the event of large quantities of the drug in the gastrointestinal tract, nausea, vomiting and cessation of bleeding in women can develop.

Treatment: no specific antidote. If necessary, symptomatic treatment should be carried out.

Medicinal interaction

In clinical practice, the interaction between the Preparation of Ovestin® and other drugs is not noted.

Estrogen metabolism can be intensified when applied in combination with compounds that induce enzymes involved in medicinal metabolism, in particular, cytochrome P450 isoenzymes, for example, such as anticonvulsants (phenobarbital, phenytoin, carbamazepine) and antimicrobial means (rifampicin, rifabutin, Neusaren, Efavirenz).

Ritonavir and Nelfinavir show inducing properties when used in combination with steroid hormones.

Herbal preparations containing hypertices (Hypericum Perforatum) can induce estrogen metabolism.

Elevated metabolism of estrogen can lead to a decrease in their clinical effect.

Estriol strengthens the effect of hypolypidemic agents.

Weakens the effects of male genital hormones, anticoagulants, antidepressants, diuretic, hypotensive, hypoglycemic drugs.

Means for general anesthesia, opioid analgesics, anxiolitics, some hypotensive drugs, ethanol reduce the effectiveness of the drug.

Folic acid and thyroid gland preparations enhance the actions of the estriol.

Conditions of vacation from pharmacies

The drug is approved for use as a means of OTC.

Terms and Storage Terms

The drug should be stored in a dry, protected from light and inaccessible to children at temperatures from 2 ° to 25 ° C. Shelf life - 3 years.

The instruction is cited by the materials of the pharmaceutical site of Vidal.

Ovrestin Cream - Method of Application and Dosage:

Dosing mode

Cream should be entered into the vagina using the calibrated applicator overnight (before bedtime).

1 Application (Applicator filled to the ring mark) contains 500 mg of cream, which corresponds to 500 μg of estriol.

In the treatment of atrophy of the mucous membrane of the lower departments of the urinary tract - 1 Application per day during the first weeks (maximum 4 weeks), followed by a gradual decline in the dose based on the relief of symptoms, until the supporting dose (i.e. 1 applique 2 times a week) .

With pre- and postoperative therapy of women in the postmenopausal period, with surgical interventions of vaginal access - 1 applique per day for 2 weeks before the operation; 1 Applique 2 times a week for 2 weeks after surgery.

With a diagnostic goal, with an unclear results of the cytological research of the cervix - 1 applique every other day during the week before taking the next smear.

When the dose pass, the missed dose must be introduced on the same day as soon as the patient remembers this (the dose should not be introduced 2 times a day). In the future, applications are carried out in accordance with the usual diagram of dosing.

At the beginning or with the continuation of the treatment of postmenopausal symptoms, it is necessary to apply the smallest efficient dose for the shortest period of time.

In women who do not receive UGT, or women who are translated from continuous reception of an oral combined drug for HGT, treatment can be started on any day. Women who are moving from the cyclic mode of reception of drugs for the UGT should begin treatment with Ovestin® cream 1 week after the cancellation of TGT drugs.

Instructions for use for patients

1. The cream is introduced into the vagina for the night (before bed).
2. Remove the cap C, turn the cap and use a sharp rod for opening.
3. Tube the Applicator to the tub.
4. Squeeze a tube to fill the applicator with cream until the piston stops.
5. Onsure the applicator C and close the tube with a cap.
6. In the lying position, the end of the applicator is introduced deep into the vagina and slowly pressed on the piston until it stops, introducing cream.

After administration of the drug from the cylinder, the piston is removed and the cylinder is washed and the piston is warm water with soap. No detergents should be applied. After that, the cylinder and piston are abundantly rinsed with clean water.

You should not lower the applicator in hot or boiling water

Amaven distinguished among the preparations of short action. As part of the active substance is an estrilla.

The component is considered a natural female hormone. In endometrials, it is distinguished by sanctulating effects, the vagina is responsible for the regeneration of the epithelium.

Due to the effective action of the preparation of Ovestin, the normal pH environment is restored, the natural microflora is normalized.

The complex helps to restore the pathological sphere, as well as increase local immunity.

The medicine is prescribed when infertility, urinary incontinence, as a preventive means of complications, with an operational process with distinguished access.

Medication is sold at an affordable price, from 250-1370 rubles.

Analogs of Russian production

Unlike the original drug, similar variants of the drug Ovestin are cheaper. In Russia, medications containing estriol are on sale there are several options.

With the choice of Russian-made medicines, you can find the following table below:

Ukrainian substitutes

Unlike the original Preparation of Ovrestin, Ukrainian substitutes have a similar effect, and have a medicinal impact on the development of urogenital disease.

Cropped women's organs and help to cope with the ailment after surgery. For sale analogues come at an average price: from 76 to 465 hryvnia.

• Follikulin
  The drug is prescribed with insufficient ovarian function. Diseases include primary and secondary amenorrhea, infertility, as well as genital hypoplasia.

  Medication helps to cope with postpartum weakness. Folliculin is prescribed under a transferred pregnancy. In the pharmacy drug sells at a price of 76 hryvnia.

• Colpotrophin.
  The medication eliminates urogenital disorders that appear after the lack of estrogen.

  The drug effectively copes with incontinence of urine, eliminates dryness, as well as itching in the vagina. After removal of the ovaries, colpofields are prescribed.

  The drug has a healing effect of vulva, as well as vagina and crotes, which are broken after delivery.

  The drug is sold at an affordable cost, it is purchased from 220.00 to 465.80 hryvnia.

• Menostar
  The medicine serves as a prophylactic agent during postmenopausal osteoporosis in women, but with the meaning that no less than 5 years have passed when menopause has occurred. Price to preparation 120 hryvnia.

Other foreign analogues

In addition to the estimated funds, there are foreign analogues of the Preparation of Ovestin.

Modern pharmacology presented such medicines that do not have the worst property and do not differ from the Soviet manufacturers.

Similar preparations of the main means of Ovestin It will restrain the same substances with an effective effect as the original product. The page presents the cheapest drugs that are available in pharmaceutical kiosks.

External data do not change, the country manufacturer tries to keep the composition and belonging to the analogues.

The manufacturer sets the final price, so the drugs are not expensive. When choosing a medicine, you need to pay attention to the side effects that are available in each instruction manual.

Related records

pharmachologic effect

Estrogenic drug. Analogue of a natural female hormone. Estimates the deficit of estrogen in women in the postmenopausal period and weakens the symptoms of postmenopause. Most effective in the treatment of urinary disorders. In atrophy of the mucous membrane of the lower sections of the urinary tract, the estrilla contributes to the normalization of the epithelium of the urinary tract and helps to restore normal microflora and physiological pH into the vagina. Increases the resistance of the epithelial cells of the urinary tract to infections and inflammation, reducing such complaints as soreness during sexual intercourse, dryness, itching in the vagina, reduces the likelihood of vaginal infections and urinary tract infections, contributes to urination normalization, prevents urinary incontinence.

Unlike other estrogen, the estriol has a short period of action, since it is held in the cells of the cells of the endometrial during a short period of time. It is assumed that the disposable administration of the daily dose does not cause endometrial proliferation. Therefore, the cyclic administration of the progestogen is not required and no bleeding occurs. In addition, it is shown that estrix does not increase the mammographic density.

Pharmacokinetics

Suction

When applying the drug inside, as well as local estriol is quickly and almost completely absorbed.

With Max estriol in the plasma is achieved after 1-2 hours after intravaginal use.

Distribution

The plasma almost all (90%) estrilla is associated with albumin and, unlike other estrogen, is practically not associated with globulin connecting sex hormones (GSPG).

Election

The removal of estriol (in the bound form) is carried out mainly by the kidneys; About 2% is excreted through the intestines unchanged. The removal of metabolites with urine begins after a few hours after applying the drug and lasts 18 hours.

Indications

- replacement hormone therapy (UGT) for the treatment of atrophy of the mucous membrane of the lower departments of the urinary tract associated with estrogenic failure;

- Pre- and postoperative treatment of women in the postmenopausal period during operations of vaginal access;

- with a diagnostic purpose with an unclear results of cytological research of the cervix (suspicion of the tumor process) against the background of atrophic changes.

Dosing mode

The accository should be entered into the vagina overnight before bedtime.

For treatment of atrophy of the mucous membrane of the lower departments of the urinary tract Assign 1 suppository / day during the first weeks, followed by a gradual decline in the dose, based on the relief of symptoms, until the supporting dose (ie 1 suppository 2 times a week).

For pre- and postoperative therapy of women in postmenopausal period, with surgical interventions of vaginal access 1 suppository / day are prescribed for 2 weeks before the operation; 1 Suppository 2 times a week for 2 weeks after surgery.

FROM diagnostic purpose with obscure results of cytological research of the cervix Assign 1 suppository every other day during the week before taking the next smear.

When the dose pass, the missed dose must be introduced on the same day as soon as the patient remembers this (the dose should not be entered 2 times / day). In the future, applications are carried out in accordance with the usual diagram of dosing.

At the beginning or in the continuation of the treatment of postmenopausal symptoms, it is necessary to apply the smallest efficient dose for the shortest period of time.

In women who do not receive UGT, or women who are translated from continuous reception of an oral combined drug for the UGT, treatment with Ovestin ® can be started on any day. Women who are moving from the cyclic mode of reception of drugs for the UGT should begin treatment with Ovestin ® 1 week after the cancellation of the TSG drugs.

Side effect

As in the case of the use of any other drug, which is applied on the surface of the mucous membranes, Ovrestin ® suppositories can sometimes cause local irritation or itching.

Sometimes Sensitivity, tension, pain, increase in the size of the mammary glands may be observed. These undesirable reactions are usually short and passing, but at the same time may indicate the use of too high dose.

Also noted acyclic bleeding, breakthrough bleeding, metroralia.

In the UGT using estrogen-pro-contained-containing drugs, the following side effects were also observed, whose relationship was not proven using OVESTIN:

- benign and malignant estrogen-independent neoplasia (endometrial cancer and mammary glands);

- venous thromboembolism (thrombosis of deep veins of the legs or pelvis, embolism of the vessels of the lungs) more often occurs when the UGT is used than in the absence of therapy;

- Myocardial infarction, stroke;

- cholelithiasis;

- skin and subcutaneous diseases (chlorism, multiform erythema, noded erythema, hemorrhagic purpura);

- Dementia;

- Raising libido.

Contraindications for use

- established, a history of or suspect of the breast cancer;

- diagnosed estrogen-dependent tumors or suspicion of them (for example, endometrial cancer);

- bleeding from vagina unclear etiology;

- untreated endometrial hyperplasia;

- the presence of venous thrombosis is currently in history;

- active or recently transferred thromboembolic disease of the arteries (for example, angina, myocardial infarction);

- liver disease in the acute stage or disease of the liver in history, after which the indicators of the liver function returned to the norm;

- Porphyria;

- installed increased sensitivity to active substance or to any of the aids of the drug.

FROM caution

If any of the following states is present or this state was noted earlier and / or worsened during preceding pregnancies or previously hormonal treatment, then such a patient should be under the direct supervision of the doctor. It should be borne in mind that these states can recur or deteriorate during treatment with Ovrestin ®, especially if present:

- Leiomioma (fibromes of uterus) or endometriosis;

- transferred thromboembolic violations or existing risk factors such violations;

- risk factors for estrogen-dependent tumors, for example, 1st degree of heredity for breast cancer;

- arterial hypertension;

- benign liver tumors (for example, liver adenoma);

- diabetes mellitus with the presence or absence of a vascular component;

- cholelithiasis;

- jaundice (including a history of preceding pregnancy);

- liver failure;

- migraine or severe headache;

- system red lupus;

- Endometrial hyperplasia in history;

- epilepsy;

- Otosclerosis;

- family hyperlipoproteinemia;

- Pancreatitis.

Application in pregnancy and breastfeeding

Ovrestin ® is contraindicated in pregnancy. In the event of pregnancy during therapy, Orestin ® preparation, treatment must be canceled immediately.

The results of most epidemiological studies conducted by the present relatively unintentional effects of estrogen on the fruit indicate the absence of teratogenic or fetotoxic effects.

Overdose

Acute toxicity of estriol in animals is very low. Overdose of the Preparation of Ovrestin ® with vaginal administration is unlikely. However, in the event of large quantities of the drug in the gastrointestinal tract, nausea, vomiting and cessation of bleeding in women can develop.

Treatment: No specific antidote. If necessary, symptomatic treatment should be carried out.

Medicinal interaction

In clinical practice, there was no interaction between the drug Ovestin ® and other drugs.

Estrogen metabolism can be intensified when applied in combination with compounds that induce enzymes involved in medicinal metabolism, in particular, cytochrome P450 isoenzymes, for example, such as anticonvulsants (phenobarbital, phenytoin, carbamazepine) and antimicrobial means (rifampicin, rifabutin, Neusaren, Efavirenz).

Ritonavir and Nelfinavir show inducing properties when used in combination with steroid hormones.

Herbal preparations containing hypertices (Hypericum Perforatum) can induce estrogen metabolism.

Elevated metabolism of estrogen can lead to a decrease in their clinical effect.

Estriol strengthens the effect of hypolypidemic agents.

Weakens the effects of male genital hormones, anticoagulants, antidepressants, diuretic, hypotensive, hypoglycemic drugs.

Means for general anesthesia, opioid analgesics, anxiolitics, some hypotensive drugs, ethanol reduce the effectiveness of the drug.

Folic acid and thyroid gland preparations enhance the actions of the estriol.

Conditions of vacation from pharmacies

The drug is approved for use as a means of OTC.

Terms and Storage Terms

The drug should be stored in a dry, protected from light and inaccessible to children at temperatures from 2 ° to 25 ° C. Shelf life - 3 years.

Application with violations of liver function

The drug is contraindicated in the disease of the liver in the acute stage or disease of the liver in history, after which the functions of the liver function returned to the norm.

With liver failure, use the drug with caution.

Application with violations of the kidney function

Estrogens can cause fluid delay, and therefore patients with impaired kidney function should be under careful control of the doctor. In the terminal stage of chronic renal failure, there must be special control in connection with the possible increase in the level of circulating active components of the Ovrestin.

special instructions

For the treatment of postmenopausal symptoms, the UGT must begin only with respect to symptoms that adversely affect the quality of life. In all cases, it is necessary to carry out a thorough assessment of the risk and benefits of treatment at least once a year. The UGT should continue only for a period of time when the benefits exceed the risk.

Medical examination / observation

Before starting or renewing the UGT, it is necessary to establish a detailed individual and family history. Based on the anamnesis, contraindications and prevention on the use of the drug, it is necessary to conduct a clinical examination, including the survey of the organs of the small pelvis and the mammary glands. During treatment, it is recommended to conduct periodic medical examinations, the frequency and character of which are individual, but at least 1 time per year. Women should be informed about the need to communicate a doctor about changes in mammary glands. Research, including mammography, must be carried out in accordance with generally accepted survey standards.

Therapy should be discontinued in the event of a contraindication and / or when the following states occur:

- jaundice and / or deterioration of the liver function;

- a significant increase in hell;

- resumption of headache by type of migraine;

- Pregnancy.

Hyperplasia Endometrial

To prevent stimulation of endometrial, the daily dose should not exceed 1 suppository (500 μg of estriol). It should not be used this maximum dose for more than 4 weeks.

Cancer of the mammary glands

Based on the results of a randomized, placebo-controlled study on the Female Health Initiative Program (WHI) and epidemiological studies, including a study of a million women (MWS), an increased risk of breast cancer in women who took estrogens, estrogen-protestagen-containing combinations or Tibolone For the UGT for several years. For the whole of HGT, the increased risk becomes noticeable after several years of use and increases with the duration of the reception, but returns to the initial level through several (maximum 5) years after the cessation of treatment.

In the study of MWS, the relative risk of breast cancer occurs when using conjugated horsepower estrogen (more) or estradiol (E2) was higher when progestogen was added, both in cyclic and continuous reception, regardless of the type of progestogen. Not received confirmation of the change in the degree of risk in various ways of administration.

In the WHI study, the use of the combined preparation of the conjugated horse estrogen and the medroxyprogesterone of acetate (easily + mR) was associated with a continuous reception with the occurrence of cancer tumors of the mammary glands, which were slightly larger in size and more often had metastases in local lymph nodes compared to placebo.

With regard to OVESHIN, such a risk is not known. In a recent population study, the case-control with the participation of 3345 women with invasive breast cancer and 3454 women in the control group it was shown that the use of estriol, unlike other estrogen, was not associated with an increase in the risk of developing breast cancer. In this regard, it is important that the patient is aware of the risk of developing breast cancer in a ratio with a known benefit of the UGT.

Venous thromboembolia

The UGT is connected with a higher relative risk of the development of venous thromboembolism (VTE), i.e. Thrombosis of deep veins or lung embolism. In one randomized controlled study and in epidemiological studies, it was found that the degree of risk for women receiving the GHT is 2-3 times higher than for patients who did not receive such treatment. It has been established that for women who do not use UGT, the number of cases of VTE, which may occur for a 5-year period, is about 3 cases for each 1000 women aged 50-59 years and 8 cases for each 1000 women aged 60-69 years. In healthy women using UGT for 5 years, the number of additional cases of VTE during the 5-year period should be 2-6 cases (on average 4) for each 1000 women aged 50-59 years and 5-15 cases (on average 9) for each 1000 women aged 60-69 years. VTE is most likely during the first year of the UGT than in a later date. In relation to OVESHIN, such a risk is unknown.

Typically, the generally accepted risk factors are the corresponding individual or family history, the obesity of a high degree (BMI\u003e 30 kg / m 2) and SLE. There is no single opinion regarding the role of varicose veins in the development of VTE.

Patients with Aite in history or with mounted thromboembolic states have an increased risk of VTE. UGT can increase this risk. In order to eliminate the predisposition to the formation of thromboms, a thorough collection of individual and family history in relation to thromboembolism or a repeated spontaneous miscarriage is needed. As long as a thorough assessment of thromboembolic factors is carried out, anticoagulant treatment should not be treated or carried out. With regard to women who are already treated with anticoagulants, careful consideration of the benefit value / risk of HRT is required.

The risk of VTE may increase with prolonged immobilization of the patient, extensive injury, the large amount of surgical intervention. After the surgical operation, it is necessary to pay special attention to preventive measures to prevent VTE. In cases where long-term immobilization is inevitable after the optional operation, in particular, after an abdominal surgical operation or orthopedic operation on the lower limbs, if possible, it is necessary to provide for a temporary termination of the UGT for 4-6 weeks before the operation. If Ovrestin ® is applied by the indication "pre-and postoperative treatment of women in the postmenopausal period with vaginal access operations" it is necessary to provide preventive treatment for preventing thrombosis.

If after the start of treatment with the preparation of Ovestin ® develops VTE, then the treatment of the drug must be discontinued. Patients should be informed about the need to immediately appeal to the doctor if they feel the symptom of potential thromboembolism (for example, painful swelling of legs, sudden chest pain, shortness of breath).

In randomized controlled studies, it has not received confirmation of the positive effect of continuous reception of a combination of conjugated estrogen and acetate (MPA) acetate (MPA) for the state of the cardiovascular system. In two large clinical studies of WHI and HERS (the study of the heart and estrogen-progestin of substitution therapy) confirmed the likelihood of a possible increase in the risk of cardiovascular diseases during the first year of application and the absence of general benefits.

There are only limited data for the UGT drugs, so there is no confidence that these results also apply to other drugs for the WGT.

Stroke

In a large randomized study (WHI), it was found that an increased risk of ischemic stroke can be considered as a side effect in healthy women during treatment with a continuous admission of a combination of conjugated estrogen and mra. For women who do not apply the GHT, the number of cases of stroke, which may occur within a 5-year period, is about 3 cases for each 1,000 women aged 50-59 years and 11 cases for each 1000 women aged 60-69 years. It has been established that for women who use conjugated estrogens and mRs for 5 years, the number of additional cases increases by 0-3 cases (on average 1) for each 1000 patients aged 50-59 years and 1-9 cases (on average 4 ) Each 1000 patients aged 60-69 years old. It is not known whether the increased risk and other drugs for the UGT are distributed.

Ovarian cancer

Long (at least 5-10 years) monotherapy with estrogens (as the UGT) women who have moved operations in the uterus are associated with an increased risk of ovarian cancer, which was established in several epidemiological studies. It has not been proven that long-term combined HGT or monotherapy with low-active estrogen (for example, Ovestin ®) has a different risk.

Other states

Estrogens can cause fluid delay, and therefore patients with impaired kidney function and cardiovascular failure must be under careful control of the doctor. In the terminal stage of chronic renal failure, there must be special control in connection with the possible increase in the level of circulating active components of the Ovrestin.

Estriol is a weak inhibitor of gonadotropin and does not have other significant effects on the endocrine system.

Not received convincing confirmation of improved cognitive function. In WHI, the test received a certificate of increased risk of possible dementia in women, which began to apply a continuously combination of conjugated estrogen and MRA in continuous mode after 65 years. It is not known whether these results are applicable to younger women who are in postmenopausal use other drugs for the UGT.

This article will help women to deal with what and how to use OVESTIN to use the age problems and determine the choice of inexpensive substitutes for this popular fund. It draws attention to important points in the instructions for the medicine and the differences in the instructions in neighboring countries, a complete list of similar drugs is given and the cost is compared.

Instructions for the use of the drug

Forms of release and composition

Ovrestin - a means of local application containing a synthetic estriol hormone. This is a preparation of female sex hormone. The tool is produced in the form of two dosage forms: creams and vaginal candles containing 0.5 milligrams of estriol.

In 1 gram of cream, the content of therapeutic substance is 1 milligram. Packaging contains 15 suppositories. Tuba accommodates 15 grams of medication. The drug is made in the Netherlands.

Indications for use

• Treatment of postmenopausal atrophy of the mucous membranes of the urinary tract and genital organs in hormonal replacement therapy lack of estrogen in patients of climacteric age
• For local treatment before and after operational interventions conducted through the surfactant access to women with postmenopausal.
• In atrophic manifestations in a smear of a cervical canal - as an additional means for diagnosis.

Drug action

Synthetic hormone Estriol repeats the structure of natural estrogen. It is able to reimburse the insufficient level of estrogen in postmenopausal, reducing clinical manifestations.

In the case of developing atrophic disorders of the cover of the mucous membranes of urinary and reproductive systems under the action of estriol, the reduction of the epithelial tissue of the mucous membranes of the urinary organs and genitals is improved and the pH indicator is restored.

It is restored by the normal vaginal microflora and the stability of epithelial tissue to damaging factors. This leads to a decrease in the sneaker of the perineum and dryness in the vagina, dispensing and urination disorders.

Due to intravaginal use of estriol, the necessary concentration is created in the application zone.

Contraindications

• pregnancy;
• mammary cancer;
• cancer endothelium of the uterus;
• vaginal hemorrhage unclear genes;
• hyperplasia epithelium of the uterine cavity;
• vessel thrombosis (including those transferred before) and complications of thrombosis and thromboembolism;
• thrombophilia;
• porphyry;
• acute lesions of the liver or disruption of the function;
• individual intolerance to estriol or other components of the drug.

Method of application and dose

The tool is used locally in the form of vaginal suppositories and cream introduced by a special applicator. Cream is dosed at 0.5 mg.

The use of healers in women with atrophy of the epithelial cover of the mucous urinary organs and genitals: 0.5 mg once every day in the first week (up to 1 month) with a further phased decrease in the dose, taking into account the course of the disease, prior to the transition to supporting one-time dosing and applied once in 14 days.

Perioperative use in postmenopausal patients with distinctive interventions: 0.5 mg daily 2 weeks before the operation and 2 weeks after it.

Application for diagnostic purposes in fuzzy cytological data Studies for the grip of the cervical channel of the uterus: 0.5 mg per day fourfold until the next taking of the material.

Side effects

• irritation or itching;
• feeling of tension and soreness in lactic glands;
• local bleeding.

Regional differences in the instructions of cream and suppositories

In addition to the approved testimony, in Russia, Ovestin is recommended for children's gynecologists for the treatment of halves of sexual lips from girls aged less than a year.

At the same time, the Russian version of the instruction does not contain data and recommendations for the use of medication in children and the schemes of destination to girls.

However, in neighboring Ukraine in the instructions clearly states that both variants of the drug do not apply to the treatment of children..

Cost of medication in pharmacies

The cost of packaging suppositories on average is 1200 rubles, changing within 1150-1270 rubles. One tube of cream costs 1350-1550 rubles, more often the price is approaching 1500 rubles.

In terms of 1 dose of medication at 0.5 mg for constant treatment, it is more profitable to use the cream, the cost of one medium dose is 50 rubles, the use of one candle will cost 30 rubles more expensive.

Comparison of Ovestin analogues

Generic vessels of candles and cream of Ovrestin are cheaper than the original medication.

Three drugs containing estriots are registered in Russia, which are produced in the form of vaginal candles:

• Ovipol Klio (Russia), the cost of 530 rubles for 15 suppositories;
• EstroCad (Germany), 10 candles for 650 rubles;
• Estrojigin (Russia).

There are two inexpensive similar means in the form of cream:

• Elvagin (Russia);
• Ornion (Russia), the average cost of 600 rubles per 15 grams.

All analogues have an estrilla, the amount of the active substance corresponds to its content in healess: the candles contain a 0.5 mg of the active substance, and the creams of 1 mg of estriol in 1 ml. Differences in auxiliary substances do not affect the result of treatment.

Basic indication for use: Atrophy of the epithelium of the mucous membranes of the urinary sphere in the post-block cell period. They are used for therapy of all states that are treated with solidin.

They have the same contraindications as the original medication.

When choosing cheap drugs, the question arises about their equivalence - the correspondence of their quality characteristics of the expensive drug. In post-Soviet countries, the therapeutic equivalence of drugs is not conducted, and bioequivalence is confirmed.

This figure characterizes the processes of receipt and removal of substances from the body and does not displays the clinical action of the drug. Therefore, it is better to choose preparations made in countries with leading quality and equivalence indicators of drugs. In the form of suppository, this is a German estroc.